FDA authorizes Aletta, the first autonomous blood-drawing robot for outpatient care

Autonomous vein targeting and vascular imaging

The Food and Drug Administration has granted authorization for Aletta, an independent robotic device engineered to draw blood from the arms of adult outpatients. Created by Vitestro, a medical robotics firm based in Utrecht, Netherlands, the system carries out the standard steps of blood collection without requiring manual needle insertion by medical personnel. To initiate the process, Aletta provides explicit guidance to the patient on how to position their arm properly inside the designated collection cradle. The machine combines two complementary imaging methods, using near-infrared light alongside Doppler ultrasound to examine the internal structure of the arm. Near-infrared illumination reveals subcutaneous veins beneath the surface of the skin, while Doppler ultrasound gathers detailed measurements on blood vessel depth and directional circulatory flow. This dual-sensing mechanism allows the robotic software to verify vessel suitability and confirm that it is not targeting an artery before committing to a puncture, halting the sequence entirely if no secure vein can be confirmed.

The robotic venipuncture and collection process

Once the system identifies an appropriate vein, it prepares the patient's skin at the target site and applies a mechanical tourniquet. Aletta then advances the needle into the targeted vein to begin drawing blood directly into standard collection containers. The robotic arm automatically swaps test tubes as each one fills, handling multiple collection vials sequentially without human touch. Upon completing the required blood draw, the mechanism smoothly withdraws the needle, discards the sharp component into an internal disposal unit, and applies an adhesive dressing over the puncture site. The automated process eliminates the physical manipulation of needles and vials by healthcare staff, executing the mechanical sequence from initial placement to post-puncture dressing.

Trial evaluations and performance metrics

Authorization from the regulatory agency followed extensive clinical data measuring the robot's ability to execute successful blood draws across patient groups. Across clinical trials, the system demonstrated successful blood extraction rates that equaled or exceeded the benchmarks established by trained human phlebotomists. In one published study, Aletta recorded a successful first-attempt puncture rate of 94.5% when a suitable vein was identified and targeted. Clinical assessments tested the platform on a diverse demographic cohort, including participants with various skin tones, different underlying health conditions, and individuals known to have difficult venous access. Adverse events documented throughout clinical testing remained rare and mild, fulfilling regulatory requirements for outpatient diagnostic procedures.

Clinical oversight and operational requirements

Despite the device's autonomous operational capabilities, the regulatory decision specifies that Aletta cannot run unattended in clinical facilities. A trained phlebotomist or qualified healthcare professional must begin each procedure, monitor the machine during operation, and step in if any anomalies occur. Following the extraction, the supervising phlebotomist performs a quality inspection to verify that all tubes were filled in the required diagnostic sequence and contain sufficient blood volumes. The operating framework permits a single trained specialist to supervise up to three Aletta stations at the same time. US regulatory officials noted that phlebotomy represents one of the most frequent clinical procedures in healthcare facilities, where persistent shortages of specialized staff often cause treatment backlogs and scheduling delays.